These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

40 related articles for article (PubMed ID: 19884561)

  • 1. Mammalian target of rapamycin: MasTOR mediator of cellular changes in pathological states?
    McNicholas CM; Berecek KH
    Hypertension; 2009 Dec; 54(6):1221-2. PubMed ID: 19884561
    [No Abstract]   [Full Text] [Related]  

  • 2. Attenuation of cardiac hypertrophy by inhibiting both mTOR and NFkappaB activation in vivo.
    Ha T; Li Y; Gao X; McMullen JR; Shioi T; Izumo S; Kelley JL; Zhao A; Haddad GE; Williams DL; Browder IW; Kao RL; Li C
    Free Radic Biol Med; 2005 Dec; 39(12):1570-80. PubMed ID: 16298682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mTOR and the control of whole body metabolism.
    Polak P; Hall MN
    Curr Opin Cell Biol; 2009 Apr; 21(2):209-18. PubMed ID: 19261457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapamycin prevents thyroid hormone-induced cardiac hypertrophy.
    Kuzman JA; O'Connell TD; Gerdes AM
    Endocrinology; 2007 Jul; 148(7):3477-84. PubMed ID: 17395699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo.
    Bodine SC; Stitt TN; Gonzalez M; Kline WO; Stover GL; Bauerlein R; Zlotchenko E; Scrimgeour A; Lawrence JC; Glass DJ; Yancopoulos GD
    Nat Cell Biol; 2001 Nov; 3(11):1014-9. PubMed ID: 11715023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shp2 negatively regulates growth in cardiomyocytes by controlling focal adhesion kinase/Src and mTOR pathways.
    Marin TM; Clemente CF; Santos AM; Picardi PK; Pascoal VD; Lopes-Cendes I; Saad MJ; Franchini KG
    Circ Res; 2008 Oct; 103(8):813-24. PubMed ID: 18757826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mammalian target of rapamycin modulates the immunoproteasome system in the heart.
    Zhang HM; Fu J; Hamilton R; Diaz V; Zhang Y
    J Mol Cell Cardiol; 2015 Sep; 86():158-67. PubMed ID: 26239133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model.
    Lang SA; Gaumann A; Koehl GE; Seidel U; Bataille F; Klein D; Ellis LM; Bolder U; Hofstaedter F; Schlitt HJ; Geissler EK; Stoeltzing O
    Int J Cancer; 2007 Apr; 120(8):1803-10. PubMed ID: 17230506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of AMP-activated protein kinase (AMPK) inhibits protein synthesis: a potential strategy to prevent the development of cardiac hypertrophy.
    Chan AY; Dyck JR
    Can J Physiol Pharmacol; 2005 Jan; 83(1):24-8. PubMed ID: 15759047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Focus Issue: demystifying mTOR signaling.
    Gough NR
    Sci Signal; 2009 Apr; 2(67):eg5. PubMed ID: 19383973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The TOR signalling network from yeast to man.
    De Virgilio C; Loewith R
    Int J Biochem Cell Biol; 2006; 38(9):1476-81. PubMed ID: 16647875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin.
    Takano A; Usui I; Haruta T; Kawahara J; Uno T; Iwata M; Kobayashi M
    Mol Cell Biol; 2001 Aug; 21(15):5050-62. PubMed ID: 11438661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes.
    Tremblay F; Gagnon A; Veilleux A; Sorisky A; Marette A
    Endocrinology; 2005 Mar; 146(3):1328-37. PubMed ID: 15576463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Rapamycin].
    Yonezawa K
    Nihon Rinsho; 2005 May; 63 Suppl 5():718-22. PubMed ID: 15954435
    [No Abstract]   [Full Text] [Related]  

  • 15. Expression of insulin-like growth factor binding protein-2 by MCF-7 breast cancer cells is regulated through the phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway.
    Martin JL; Baxter RC
    Endocrinology; 2007 May; 148(5):2532-41. PubMed ID: 17289850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The histone demethylase PHF8 represses cardiac hypertrophy upon pressure overload.
    Liu X; Wang X; Bi Y; Bu P; Zhang M
    Exp Cell Res; 2015 Jul; 335(1):123-34. PubMed ID: 25921086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance.
    Khamzina L; Veilleux A; Bergeron S; Marette A
    Endocrinology; 2005 Mar; 146(3):1473-81. PubMed ID: 15604215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of phosphatidylinositol 3-kinase, Akt, and mammalian target of rapamycin is necessary for hypoxia-induced pulmonary artery adventitial fibroblast proliferation.
    Gerasimovskaya EV; Tucker DA; Stenmark KR
    J Appl Physiol (1985); 2005 Feb; 98(2):722-31. PubMed ID: 15501927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists.
    Carraway H; Hidalgo M
    Breast Cancer Res; 2004; 6(5):219-24. PubMed ID: 15318929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-451 exacerbates lipotoxicity in cardiac myocytes and high-fat diet-induced cardiac hypertrophy in mice through suppression of the LKB1/AMPK pathway.
    Kuwabara Y; Horie T; Baba O; Watanabe S; Nishiga M; Usami S; Izuhara M; Nakao T; Nishino T; Otsu K; Kita T; Kimura T; Ono K
    Circ Res; 2015 Jan; 116(2):279-88. PubMed ID: 25362209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.